Congestive Heart Failure (CHF) Treatment Devices Market by Product Type (Pacemakers (Implantable, Pacemakers), CRT (CRT-P, CRT-D), ICDs (T-ICDs, S-ICDs), VADs (LVAD, RVAD, BIVAD)) - Global Opportunity Analysis and Industry Forecast, 2015 - 2022
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
The world CHF treatment devices market was evaluated at $10,127.2 million in 2015, and is estimated to reach $14,823.3 million by 2022, with a CAGR of 5.5% over the forecast period. This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.
The report segments the world CHF treatment devices market based on product type, namely, pacemakers, cardiac resynchronization therapy (CRT) devices, implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). Pacemaker is further segmented into dual-chamber pacemakers and single-chamber pacemakers. CRT devices is segmented into two major types, namely, CRT-P and CRT-D. ICDs is further segmented into transvenous implantable cardioverter defibrillator (T-ICDs) and subcutaneous implantable cardioverter defibrillator (S-ICDs). VADs is also segmented into left ventricular assist device (LVAD), right ventricular assist device (RVAD), and biventricular assist device (BIVAD). ICDs was the highest revenue-generating segment in 2015, owing to the stressful hyperactive lifestyle, unhealthy food habits, and growing number of aging population. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA regions.
The key players in this market adopted product development and product launch as their key strategies to keep pace with the changing demands of consumers. Furthermore, companies launched cost-effective and technologically efficient products to strengthen their market position. The report provides a comprehensive analysis of the key players operating in the world CHF treatment devices market, such as Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc.
Key Benefits
Congestive Heart Failure (CHF) Treatment Devices Market, By Product
The world CHF treatment devices market was evaluated at $10,127.2 million in 2015, and is estimated to reach $14,823.3 million by 2022, with a CAGR of 5.5% over the forecast period. This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.
The report segments the world CHF treatment devices market based on product type, namely, pacemakers, cardiac resynchronization therapy (CRT) devices, implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). Pacemaker is further segmented into dual-chamber pacemakers and single-chamber pacemakers. CRT devices is segmented into two major types, namely, CRT-P and CRT-D. ICDs is further segmented into transvenous implantable cardioverter defibrillator (T-ICDs) and subcutaneous implantable cardioverter defibrillator (S-ICDs). VADs is also segmented into left ventricular assist device (LVAD), right ventricular assist device (RVAD), and biventricular assist device (BIVAD). ICDs was the highest revenue-generating segment in 2015, owing to the stressful hyperactive lifestyle, unhealthy food habits, and growing number of aging population. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA regions.
The key players in this market adopted product development and product launch as their key strategies to keep pace with the changing demands of consumers. Furthermore, companies launched cost-effective and technologically efficient products to strengthen their market position. The report provides a comprehensive analysis of the key players operating in the world CHF treatment devices market, such as Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc.
Key Benefits
- The study provides an in-depth analysis of the world CHF treatment devices market with current trends and future estimations to elucidate the imminent investment pockets in the market.
- The report provides a quantitative analysis from 2015 to 2022 that would enable the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the world CHF treatment devices market, by product, helps in understanding the various types of devices used for the treatment of CHF and other related cardiac conditions.
- Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
- SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.
Congestive Heart Failure (CHF) Treatment Devices Market, By Product
- Pacemakers, By Type
- Implantable Pacemakers
- External Pacemakers
- Cardiac Resynchronization Therapy (CRT), By Type
- Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
- Cardiac Resynchronization Therapy-Defibrillators (CRT-D)
- Implantable Cardioverter Defibrillators (ICDs), By Type
- Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
- Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
- Ventricular Assist Devices (VADs), By Type
- Left Ventricular Assist Device (LVAD)
- Right Ventricular Assist Device (RVAD)
- Biventricular Assist Device (BIVAD)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.5.1 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2027 ($Million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 High competition and fragmented market moderates the power of the suppliers
3.3.2 Scattered and large number of buyers moderates their bargaining power
3.3.3 High capital investment moderates the threat of new entrants
3.3.4 High intensity of rivalry
3.3.5 Unavailability of substitutes lowers the threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Growing incidences of congestive heart failures
3.5.1.2 Technological advancements in CHF treatment devices
3.5.1.3 Increasing patient awareness
3.5.1.4 Presence of high-unmet medical needs
3.5.2 Restraints
3.5.2.1 Limited insurance coverage and high cost of the CHF treatment devices
3.5.2.2 unfavorable preference to pharmaceutical interventions (drugs) over CHF treatment devices
3.5.3 Opportunities
3.5.3.1 Lucrative opportunities in emerging economies
3.5.3.2 Development of new MRI-labeled devices
CHAPTER 4 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCT
4.1 Pacemakers
4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.1.4 Implantable Pacemakers
4.1.4.1 Market size and forecast
4.1.5 External Pacemakers
4.1.5.1 Market size and forecast
4.2 Cardiac resynchronization therapy (CRT)
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 CRT-P (CRT with pacemaker function)
4.2.4.1 Market size and forecasts
4.2.5 CRT-D (CRT with pacemaker and ICD function)
4.2.5.1 Market size and forecasts
4.3 Implantable cardioverter defibrillators (ICDs)
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.2.1 Market size and forecast
4.3.3 Transvenous implantable cardioverter defibrillator (T-ICDs)
4.3.3.1 Market size and forecasts
4.3.4 Subcutaneous implantable cardioverter defibrillator (S-ICDs)
4.3.4.1 Market size and forecasts
4.4 Ventricular Assist Devices (VADs)
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 Left Ventricular assist device (LVAD)
4.4.4.1 Market size and forecasts
4.4.5 Right ventricular assist device (RVAD)
4.4.5.1 Market size and forecasts
4.4.6 Biventricular Assist Device (BIVAD)
4.4.6.1 Market size and forecasts
CHAPTER 5 WORLD CHF TREATMENT DEVICES MARKET, BY GEOGRAPHY, 2015-2022
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 U.S.
5.2.4.1 Market size and forecast
5.2.5 Canada
5.2.5.1 Market size and forecast
5.2.6 Mexico
5.2.6.1 Market size and forecast
5.3 Europe
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.3.4 Germany
5.3.4.1 Market size and forecast
5.3.5 France
5.3.5.1 Market size and forecast
5.3.6 U.K.
5.3.6.1 Market size and forecast
5.3.7 Rest of Europe
5.3.7.1 Market size and forecast
5.4 Asia-Pacific
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 India
5.4.4.1 Market size and forecast
5.4.5 China
5.4.5.1 Market size and forecast
5.4.6 Japan
5.4.6.1 Market size and forecast
5.4.7 Rest of Asia-Pacific
5.4.7.1 Market size and forecast
5.5 LAMEA
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.5.4 Latin America
5.5.4.1 Market size and forecast
5.5.5 Middle East
5.5.5.1 Market size and forecast
5.5.6 Africa
5.5.6.1 Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1 Abiomed, Inc.
6.1.1 Company overview
6.1.2 Operating business segments
6.1.3 Business performance
6.1.4 Key strategic moves & developments
6.1.5 SWOT analysis
6.2 Berlin Heart GmbH
6.2.1 Company overview
6.2.2 Operating business segments
6.2.3 Key strategic move & development
6.2.4 SWOT analysis
6.3 Biotronik SE & Co. KG
6.3.1 Company overview
6.3.2 Operating business segments
6.3.3 Key strategic moves & developments
6.3.4 SWOT analysis
6.4 Boston Scientific Corporation
6.4.1 Company overview
6.4.2 Operating business segments
6.4.3 Business performance
6.4.4 Key strategic moves & developments
6.4.5 SWOT analysis
6.5 HeartWare International, Inc.
6.5.1 Company overview
6.5.2 Operating business segments
6.5.3 Business performance
6.5.4 Key strategic moves & developments
6.5.5 SWOT analysis
6.6 Jarvik Heart, Inc.
6.6.1 Company overview
6.6.2 Operating business segments
6.6.3 Key strategic moves & developments
6.6.4 SWOT analysis
6.7 LivaNova PLC
6.7.1 Company overview
6.7.2 Operating business segments
6.7.3 Business performance
6.7.4 Key strategic moves & developments
6.7.5 SWOT analysis
6.8 Medtronic plc
6.8.1 Company overview
6.8.2 Operating business segments
6.8.3 Business performance
6.8.4 Key strategic moves & developments
6.8.5 SWOT analysis
6.9 ReliantHeart, Inc.
6.9.1 Company overview
6.9.2 Operating business segments
6.9.3 Key strategic moves & developments
6.9.4 SWOT analysis
6.10 St. Jude Medical, Inc.
6.10.1 Company overview
6.10.2 Operating business segments
6.10.3 Business performance
6.10.4 Key strategic moves & developments
6.10.5 SWOT analysis
List of Figures
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.5.1 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2027 ($Million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 High competition and fragmented market moderates the power of the suppliers
3.3.2 Scattered and large number of buyers moderates their bargaining power
3.3.3 High capital investment moderates the threat of new entrants
3.3.4 High intensity of rivalry
3.3.5 Unavailability of substitutes lowers the threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Growing incidences of congestive heart failures
3.5.1.2 Technological advancements in CHF treatment devices
3.5.1.3 Increasing patient awareness
3.5.1.4 Presence of high-unmet medical needs
3.5.2 Restraints
3.5.2.1 Limited insurance coverage and high cost of the CHF treatment devices
3.5.2.2 unfavorable preference to pharmaceutical interventions (drugs) over CHF treatment devices
3.5.3 Opportunities
3.5.3.1 Lucrative opportunities in emerging economies
3.5.3.2 Development of new MRI-labeled devices
CHAPTER 4 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCT
4.1 Pacemakers
4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.1.4 Implantable Pacemakers
4.1.4.1 Market size and forecast
4.1.5 External Pacemakers
4.1.5.1 Market size and forecast
4.2 Cardiac resynchronization therapy (CRT)
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 CRT-P (CRT with pacemaker function)
4.2.4.1 Market size and forecasts
4.2.5 CRT-D (CRT with pacemaker and ICD function)
4.2.5.1 Market size and forecasts
4.3 Implantable cardioverter defibrillators (ICDs)
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.2.1 Market size and forecast
4.3.3 Transvenous implantable cardioverter defibrillator (T-ICDs)
4.3.3.1 Market size and forecasts
4.3.4 Subcutaneous implantable cardioverter defibrillator (S-ICDs)
4.3.4.1 Market size and forecasts
4.4 Ventricular Assist Devices (VADs)
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 Left Ventricular assist device (LVAD)
4.4.4.1 Market size and forecasts
4.4.5 Right ventricular assist device (RVAD)
4.4.5.1 Market size and forecasts
4.4.6 Biventricular Assist Device (BIVAD)
4.4.6.1 Market size and forecasts
CHAPTER 5 WORLD CHF TREATMENT DEVICES MARKET, BY GEOGRAPHY, 2015-2022
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 U.S.
5.2.4.1 Market size and forecast
5.2.5 Canada
5.2.5.1 Market size and forecast
5.2.6 Mexico
5.2.6.1 Market size and forecast
5.3 Europe
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.3.4 Germany
5.3.4.1 Market size and forecast
5.3.5 France
5.3.5.1 Market size and forecast
5.3.6 U.K.
5.3.6.1 Market size and forecast
5.3.7 Rest of Europe
5.3.7.1 Market size and forecast
5.4 Asia-Pacific
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 India
5.4.4.1 Market size and forecast
5.4.5 China
5.4.5.1 Market size and forecast
5.4.6 Japan
5.4.6.1 Market size and forecast
5.4.7 Rest of Asia-Pacific
5.4.7.1 Market size and forecast
5.5 LAMEA
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.5.4 Latin America
5.5.4.1 Market size and forecast
5.5.5 Middle East
5.5.5.1 Market size and forecast
5.5.6 Africa
5.5.6.1 Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1 Abiomed, Inc.
6.1.1 Company overview
6.1.2 Operating business segments
6.1.3 Business performance
6.1.4 Key strategic moves & developments
6.1.5 SWOT analysis
6.2 Berlin Heart GmbH
6.2.1 Company overview
6.2.2 Operating business segments
6.2.3 Key strategic move & development
6.2.4 SWOT analysis
6.3 Biotronik SE & Co. KG
6.3.1 Company overview
6.3.2 Operating business segments
6.3.3 Key strategic moves & developments
6.3.4 SWOT analysis
6.4 Boston Scientific Corporation
6.4.1 Company overview
6.4.2 Operating business segments
6.4.3 Business performance
6.4.4 Key strategic moves & developments
6.4.5 SWOT analysis
6.5 HeartWare International, Inc.
6.5.1 Company overview
6.5.2 Operating business segments
6.5.3 Business performance
6.5.4 Key strategic moves & developments
6.5.5 SWOT analysis
6.6 Jarvik Heart, Inc.
6.6.1 Company overview
6.6.2 Operating business segments
6.6.3 Key strategic moves & developments
6.6.4 SWOT analysis
6.7 LivaNova PLC
6.7.1 Company overview
6.7.2 Operating business segments
6.7.3 Business performance
6.7.4 Key strategic moves & developments
6.7.5 SWOT analysis
6.8 Medtronic plc
6.8.1 Company overview
6.8.2 Operating business segments
6.8.3 Business performance
6.8.4 Key strategic moves & developments
6.8.5 SWOT analysis
6.9 ReliantHeart, Inc.
6.9.1 Company overview
6.9.2 Operating business segments
6.9.3 Key strategic moves & developments
6.9.4 SWOT analysis
6.10 St. Jude Medical, Inc.
6.10.1 Company overview
6.10.2 Operating business segments
6.10.3 Business performance
6.10.4 Key strategic moves & developments
6.10.5 SWOT analysis
List of Figures
LIST OF TABLES
TABLE 1 WORLD CHF TREATMENT DEVIVES MARKET, MODERATE GROWTH SCENARIO, VALUE, 2022-2027 ($MILLION)
TABLE 2 WORLD CHF TREATMENT DEVIVES MARKET VALUE, RAPID GROWTH SCENARIO, 20222027 ($MILLION)
TABLE 3 WORLD CHF TREATMENT DEVIVES MARKET VALUE, DIMINISHING GROWTH SCENARIO, 20222027 ($MILLION)
TABLE 4 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 20152022 ($MILLION)
TABLE 5 WORLD PACEMAKERS MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 6 WORLD PACEMAKERS MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 7 WORLD CRT MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 8 WORLD CRT MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 9 WORLD ICDS MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 10 WORLD ICDS MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 11 WORLD VADS MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 12 WORLD VADS MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 13 CHF TREATMENT DEVICES MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 14 NORTH AMERICA: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 15 NORTH AMERICA: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 16 EUROPE: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 17 EUROPE: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 18 ASIA-PACIFIC: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 19 ASIA-PACIFIC: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 20 LAMEA: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 21 LAMEA: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 22 ABIOMED: COMPANY SNAPSHOT
TABLE 23 BERLIN HEART: COMPANY SNAPSHOT
TABLE 24 BIOTRONIK: COMPANY SNAPSHOT
TABLE 25 BIOTRONIK: OPERATING SEGMENTS
TABLE 26 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 27 BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
TABLE 28 HEARTWARE: COMPANY SNAPSHOT
TABLE 29 JARVIK HEART: COMPANY SNAPSHOT
TABLE 30 LIVANOVA: COMPANY SNAPSHOT
TABLE 31 LIVANOVA: OPERATING SEGMENTS
TABLE 32 MEDTRONIC: COMPANY SNAPSHOT
TABLE 33 MEDTRONIC: OPERATING SEGMENTS
TABLE 34 RELIANTHEART: COMPANY SNAPSHOT
TABLE 35 ST. JUDE MEDICAL: COMPANY SNAPSHOT
TABLE 1 WORLD CHF TREATMENT DEVIVES MARKET, MODERATE GROWTH SCENARIO, VALUE, 2022-2027 ($MILLION)
TABLE 2 WORLD CHF TREATMENT DEVIVES MARKET VALUE, RAPID GROWTH SCENARIO, 20222027 ($MILLION)
TABLE 3 WORLD CHF TREATMENT DEVIVES MARKET VALUE, DIMINISHING GROWTH SCENARIO, 20222027 ($MILLION)
TABLE 4 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 20152022 ($MILLION)
TABLE 5 WORLD PACEMAKERS MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 6 WORLD PACEMAKERS MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 7 WORLD CRT MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 8 WORLD CRT MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 9 WORLD ICDS MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 10 WORLD ICDS MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 11 WORLD VADS MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 12 WORLD VADS MARKET, BY TYPE, 20152022 ($MILLION)
TABLE 13 CHF TREATMENT DEVICES MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
TABLE 14 NORTH AMERICA: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 15 NORTH AMERICA: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 16 EUROPE: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 17 EUROPE: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 18 ASIA-PACIFIC: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 19 ASIA-PACIFIC: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 20 LAMEA: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 21 LAMEA: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) ($MILLION)
TABLE 22 ABIOMED: COMPANY SNAPSHOT
TABLE 23 BERLIN HEART: COMPANY SNAPSHOT
TABLE 24 BIOTRONIK: COMPANY SNAPSHOT
TABLE 25 BIOTRONIK: OPERATING SEGMENTS
TABLE 26 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 27 BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
TABLE 28 HEARTWARE: COMPANY SNAPSHOT
TABLE 29 JARVIK HEART: COMPANY SNAPSHOT
TABLE 30 LIVANOVA: COMPANY SNAPSHOT
TABLE 31 LIVANOVA: OPERATING SEGMENTS
TABLE 32 MEDTRONIC: COMPANY SNAPSHOT
TABLE 33 MEDTRONIC: OPERATING SEGMENTS
TABLE 34 RELIANTHEART: COMPANY SNAPSHOT
TABLE 35 ST. JUDE MEDICAL: COMPANY SNAPSHOT
LIST OF FIGURES
FIG. 1 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCTS, 2015 VS 2022, ($MILLION)
FIG. 2 CHF TREATMENT DEVICES MARKET. BY GEOGRAPHY, 2015
FIG. 3 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (20222027)
FIG. 4 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (20222027)
FIG. 5 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2027)
FIG. 6 TOP INVESTMENT POCKETS IN WORLD CHF TREATMENT DEVICES MARKET
FIG. 7 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIG. 8 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 9 PORTERS FIVE FORCES ANALYSIS
FIG. 10 MARKET SHARE ANALYSIS, 2015
FIG. 11 CATEGORIZATION OF AGEING POPLUATION ON THE BASIS OF REGIONS (2013)
FIG. 12 WORLD IMPLANTABLE PACEMAKERS MARKET, (2015-2022) ($MILLION)
FIG. 13 WORLD EXTERNAL PACEMAKERS MARKET, (2015-2022) ($MILLION)
FIG. 14 WORLD CRT-P MARKET, (2015-2022) ($MILLION)
FIG. 15 WORLD CRT-D MARKET, (2015-2022) ($MILLION)
FIG. 16 WORLD T-ICDS MARKET, (2015-2022) ($MILLION)
FIG. 17 WORLD S-ICDS MARKET, (2015-2022) ($MILLION)
FIG. 18 WORLD LVAD MARKET, (2015-2022) ($MILLION)
FIG. 19 WORLD RVAD MARKET, (2015-2022) ($MILLION)
FIG. 20 WORLD BIVAD MARKET, (2015-2022) ($MILLION)
FIG. 21 U.S. CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 22 CANADA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 23 MEXICO CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 24 GERMANY CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 25 FRANCE CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 26 U.K. CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 27 REST OF EUROPE CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 28 INDIA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 29 CHINA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 30 JAPAN CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 31 REST OF ASIA-PACIFIC CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 32 LATIN AMERICA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 33 MIDDLE EAST CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 34 AFRICA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 35 ABIOMED: NET REVENUE, 20132015 ($MILLION)
FIG. 36 ABIOMED: SWOT ANALYSIS
FIG. 37 BERLIN HEART: SWOT ANALYSIS
FIG. 38 BIOTRONIK: SWOT ANALYSIS
FIG. 39 BOSTON SCIENTIFIC CORPORATION: NET SALES, 20132015, ($MILLION)
FIG. 40 BOSTON SCIENTIFIC CORPORATION: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIG. 41 BOSTON SCIENTIFIC CORPORATION: RHYTHM MANAGEMENT REVENUE BY SUB-SEGMENT, 2015 (%)
FIG. 42 BOSTON SCIENTIFIC CORPORATION: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 43 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS
FIG. 44 HEARTWARE: NET REVENUE, 20132015 ($MILLION)
FIG. 45 HEARTWARE: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 46 HEARTWARE - SWOT ANALYSIS
FIG. 47 JARVIK HEART: SWOT ANALYSIS
FIG. 48 LIVANOVA: NET SALES, 20132015 ($MILLION)
FIG. 49 LIVANOVA: REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 50 LIVANOVA: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 51 LIVANOVA: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 52 LIVANOVA: SWOT ANALYSIS
FIG. 53 MEDTRONIC: NET SALES, 20132015 ($MILLION)
FIG. 54 MEDTRONIC: REVENUE BY SEGMENT, 2015 (%)
FIG. 55 MEDTRONIC: CARDIAC AND VASCULAR GROUP REVENUE BY SUB-SEGMENT, 2015 (%)
FIG. 56 MEDTRONIC: SWOT ANALYSIS
FIG. 57 RELIANTHEART: SWOT ANALYSIS
FIG. 58 ST. JUDE MEDICAL: NET SALES, 20132015 ($MILLION)
FIG. 59 ST. JUDE MEDICAL: REVENUE BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 60 ST. JUDE MEDICAL: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 61 ST. JUDE MEDICAL: SWOT ANALYSIS
FIG. 1 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCTS, 2015 VS 2022, ($MILLION)
FIG. 2 CHF TREATMENT DEVICES MARKET. BY GEOGRAPHY, 2015
FIG. 3 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (20222027)
FIG. 4 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (20222027)
FIG. 5 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2027)
FIG. 6 TOP INVESTMENT POCKETS IN WORLD CHF TREATMENT DEVICES MARKET
FIG. 7 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIG. 8 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 9 PORTERS FIVE FORCES ANALYSIS
FIG. 10 MARKET SHARE ANALYSIS, 2015
FIG. 11 CATEGORIZATION OF AGEING POPLUATION ON THE BASIS OF REGIONS (2013)
FIG. 12 WORLD IMPLANTABLE PACEMAKERS MARKET, (2015-2022) ($MILLION)
FIG. 13 WORLD EXTERNAL PACEMAKERS MARKET, (2015-2022) ($MILLION)
FIG. 14 WORLD CRT-P MARKET, (2015-2022) ($MILLION)
FIG. 15 WORLD CRT-D MARKET, (2015-2022) ($MILLION)
FIG. 16 WORLD T-ICDS MARKET, (2015-2022) ($MILLION)
FIG. 17 WORLD S-ICDS MARKET, (2015-2022) ($MILLION)
FIG. 18 WORLD LVAD MARKET, (2015-2022) ($MILLION)
FIG. 19 WORLD RVAD MARKET, (2015-2022) ($MILLION)
FIG. 20 WORLD BIVAD MARKET, (2015-2022) ($MILLION)
FIG. 21 U.S. CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 22 CANADA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 23 MEXICO CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 24 GERMANY CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 25 FRANCE CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 26 U.K. CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 27 REST OF EUROPE CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 28 INDIA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 29 CHINA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 30 JAPAN CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 31 REST OF ASIA-PACIFIC CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 32 LATIN AMERICA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 33 MIDDLE EAST CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 34 AFRICA CHF TREATMENT DEVICES MARKET, (2015-2022) ($MILLION)
FIG. 35 ABIOMED: NET REVENUE, 20132015 ($MILLION)
FIG. 36 ABIOMED: SWOT ANALYSIS
FIG. 37 BERLIN HEART: SWOT ANALYSIS
FIG. 38 BIOTRONIK: SWOT ANALYSIS
FIG. 39 BOSTON SCIENTIFIC CORPORATION: NET SALES, 20132015, ($MILLION)
FIG. 40 BOSTON SCIENTIFIC CORPORATION: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIG. 41 BOSTON SCIENTIFIC CORPORATION: RHYTHM MANAGEMENT REVENUE BY SUB-SEGMENT, 2015 (%)
FIG. 42 BOSTON SCIENTIFIC CORPORATION: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 43 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS
FIG. 44 HEARTWARE: NET REVENUE, 20132015 ($MILLION)
FIG. 45 HEARTWARE: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 46 HEARTWARE - SWOT ANALYSIS
FIG. 47 JARVIK HEART: SWOT ANALYSIS
FIG. 48 LIVANOVA: NET SALES, 20132015 ($MILLION)
FIG. 49 LIVANOVA: REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 50 LIVANOVA: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 51 LIVANOVA: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 52 LIVANOVA: SWOT ANALYSIS
FIG. 53 MEDTRONIC: NET SALES, 20132015 ($MILLION)
FIG. 54 MEDTRONIC: REVENUE BY SEGMENT, 2015 (%)
FIG. 55 MEDTRONIC: CARDIAC AND VASCULAR GROUP REVENUE BY SUB-SEGMENT, 2015 (%)
FIG. 56 MEDTRONIC: SWOT ANALYSIS
FIG. 57 RELIANTHEART: SWOT ANALYSIS
FIG. 58 ST. JUDE MEDICAL: NET SALES, 20132015 ($MILLION)
FIG. 59 ST. JUDE MEDICAL: REVENUE BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 60 ST. JUDE MEDICAL: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 61 ST. JUDE MEDICAL: SWOT ANALYSIS
